Hot flush relief without oestrogen: exercise, soy and gabapentin showed promise

Hot flushes and night sweats, known medically as vasomotor symptoms, are among the most disruptive features of the menopausal transition. Oestrogen is the classic treatment, but plenty of women either cannot take it or would rather not, which makes the question of what else actually works a practical one rather than an academic one. This review set out to systematically assess the efficacy and safety of nonestrogen treatments for menopause-associated vasomotor symptoms, deliberately excluding symptoms caused by cancer or chemotherapy, where the picture is different.

The authors searched MEDLINE from 1966 and EMBASE from 1959, both through February 2004, for English-language articles on treating perimenopausal and postmenopausal vasomotor symptoms, and checked the reference lists of relevant papers for more. They placed the greatest weight on trials where participants were randomly assigned and neither they nor the researchers knew who received placebo, since these give the most reliable efficacy and safety data. Prescription options reviewed included clonidine, danazol, gabapentin, methyldopa, mirtazapine, progestins, propranolol, SSRIs and venlafaxine; nonprescription options included black cohosh, dong quai, evening primrose oil, physical activity, phytoestrogens and red clover.

The treatments the review concluded had been shown safe and effective for short-term use were a mixed bag spanning lifestyle, supplements and prescriptions: black cohosh, exercise, gabapentin, medroxyprogesterone acetate, SSRIs with paroxetine named specifically, and soy protein. For megestrol acetate and venlafaxine, initial small reports were suggestive of efficacy but not yet conclusive. The remaining options reviewed, including dong quai, evening primrose oil and red clover, were not among those the authors concluded had demonstrated effectiveness.

This review mapped the nonhormonal landscape at a moment when many women were seeking alternatives to oestrogen, and its central message, that credible options exist across lifestyle, supplement and prescription categories, has shaped practice since. Its limits are equally clear: the search closed in February 2004, the endorsements cover short-term use only, and several findings rested on small initial reports. How these options compare with each other, and how they hold up over longer use, were open questions the review could not answer.

If hot flushes are an issue and oestrogen is not an option you want or can use, this is a reason to know the menu is longer than folklore suggests: regular exercise and soy protein sat alongside prescription routes like gabapentin and paroxetine in the group with short-term trial support. It is equally a reason for healthy scepticism about remedies that did not make that list. Given the review's age, anything here is a starting point for a conversation with a clinician, not the final word.